A recent study published in the peer-reviewed journal Managed Care affirms VeriStrat; demonstrates the value of the VeriStrat lung cancer test
Interim study results: Veristrat testing impacts lung cancer treatment in all stages; early stage patients get significantly different treatments after test
The Positive Bioscience agreement will make GeneStrat and VeriStrat tests available in India
A new study demonstrates that VeriStrat can help physicians improve quality care and cancer care planning for patients with advanced lung cancer.
VeriStrat test saved an average of $1,050 per patient while improving survival outcomes (as compared to patients treated without the use of the test).
Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.
Clin-TOF successfully integrated into VeriStrat® workflow
Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.
With positive coverage decisions from BCBS Florida and HCSC, 200 million Americans now have insurance coverage for VeriStrat testing.
VeriStrat and Epidermal Growth Factor Receptor Mutation Status Study results presented at 16th World Conference on Lung Cancer